(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumors have certain genetic mutations may respond particularly well to this combination approach, according to the results of a clinical trial published in European Urology.

Related Links:

ConclusionsCost-effectiveness and WTP thresholds vary between countries. Compared with the other countries examined, US drug prices were found to be the highest, leading to the highest ICER. With standard WTP thresholds, pembrolizumab may be considered cost-effective in the US but not in the other countries examined.Patient summaryThis article assessed the cost-effectiveness of pembrolizumab for the treatment of patients with metastatic bladder cancer who had previously failed one treatment regimen. It would cost $122 557 in the United States, $91 995 in the United Kingdom, $90 099 in Canada, and $99 966 in Australia to ga…

Source: European UrologyCategory: Urology & Nephrology Source Type: research

Oncologist Dr. Arek Dudek at Regions Hospital Cancer Care Center in St. Paul, Minnesota, believes his clinical trial involving a novel immunotherapy combination could change the way doctors treat pleural mesothelioma.
Dudek is opening the only Phase II trial evaluating the combination of nivalumab (Opdivo) and ramucirumab (Cyramza) for previously treated mesothelioma patients.
“This strategy – if successful, like we think it will be – could make treatment with chemotherapy obsolete,” Dudek told Asbestos.com. “People can be really excited about this one.”
He based his optimism on the pote…

ZURICH (Reuters) – The European Medicines Agency on Friday recommended restricting use of two immunotherapies, one from Roche and the other from Merck, in initial bladder cancer treatment, saying they may not work as well as chemotherapy in some patients.

Source: Reuters: HealthCategory: Consumer Health News Tags: healthNews Source Type: news

Opinion statementMuscle-invasive bladder cancer (MIBC) has high metastatic potential at diagnosis but is still often curable with aggressive management, which may give patients the best odds for a favorable clinical outcome. The standard-of-care management of MIBC includes a radical cystectomy and pelvic lymph node dissection. If the patient is cisplatin-eligible, neoadjuvant cisplatin-based combination chemotherapy should also be given. Post-surgery adjuvant treatments include observation, chemotherapy, radiation, or enrollment in a clinical trial. Several adjuvant immunotherapy trials with checkpoint inhibitors, which bl…

We describe the role of interactions basally established between urothelial tumor cells and cellular and molecular elements of the immune system of the patients with ulterior antitumor effector capacity. After intravesical BCG therapy and its interaction, we describe the various phases of its mechanism of action, namely fixation, internalization and triggering of the lytic cytotoxic antitumor response, and its integration in the current intravesical treatment regimens The implication of all these mechanisms in the varied capacity of clinical response observed in patients, reviewing the current status of knowledge of BCG me…

This article provides an overview of bladder cancer and its current management practices, underlining the continued role of smoking as the predominant risk factor in the disease’s development. The management of bladder cancer is governed by specific guidelines. Management of non-muscle-invasive cancers, including surgical intervention with transurethral resection, and intravesical therapy using chemotherapy and immunotherapy agents, is discussed. Cystectomy (removal of the bladder), is sometimes necessary. Treatments are effective in reducing tumour recurrence, but the effects of the risks and side-effects on the individua…

Condition:   Bladder Cancer Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Procedure: Radical cystectomy Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting

Source link


Please enter your comment!
Please enter your name here